Simulations Plus, Inc. (SLP)
| Market Cap | 570.71M |
| Revenue (ttm) | 70.01M |
| Net Income (ttm) | 9.95M |
| Shares Out | 20.07M |
| EPS (ttm) | 0.49 |
| PE Ratio | 58.63 |
| Forward PE | 41.04 |
| Dividend | $0.18 (0.63%) |
| Ex-Dividend Date | Jul 29, 2024 |
| Volume | 20,716 |
| Open | 28.55 |
| Previous Close | 28.58 |
| Day's Range | 28.24 - 28.84 |
| 52-Week Range | 27.07 - 51.22 |
| Beta | 0.77 |
| Analysts | Buy |
| Price Target | 51.40 (+80.73%) |
| Earnings Date | Jan 7, 2025 |
About SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models,... [Read more]
Financial Performance
In 2024, Simulations Plus's revenue was $70.01 million, an increase of 17.52% compared to the previous year's $59.58 million. Earnings were $9.95 million, a decrease of -0.07%.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for SLP stock is "Buy." The 12-month stock price forecast is $51.4, which is an increase of 80.73% from the latest price.
News
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and Conference Call Date
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions...
Simulations Plus to Participate in the BTIG Digital Health Forum
LANCASTER, Calif.--(BUSINESS WIRE)--CEO of Simulations Plus, Shawn O'Connor, will participate in a panel discussion at the virtual BTIG Digital Health Forum on Monday, November 25, 2024.
Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, in partnership with the University of Connecticut, was awarded a new FDA grant to investigate additional LAI product technologies.
Simulations Plus to Participate in the Stephens Annual Investment Conference
LANCASTER, Calif.--(BUSINESS WIRE)--Shawn O'Connor, CEO, will participate in a fireside chat at the Stephens Annual Investment Conference on Wednesday, November 20, 2024 at 12:00pm ET.
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, with industry and academic partners, was awarded a new FDA grant to validate new methods for more efficient drug development.
Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript
Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript
Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported fiscal year 2024 total revenues of $70 million, 18% over fiscal 2023, and 4th quarter total revenues of $18.7 million.
Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a conference call & webcast on October 23, 2024, at 5pm ET to discuss 4th quarter & fiscal year 2024 financial results.
Simulations Plus and the University of Southern California Secure NIH Grant to Develop New AI Drug Discovery Offerings
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, in partnership with USC, is awarded a new research grant from the NIH to develop new AI-driven Drug Design methods.
Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be participating in Morgan Stanley's Global Healthcare Conference on September 6, 2024, in New York City.
Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced strategic changes in leadership and the structure of its business units to optimize operations and support future growth.
Simulations Plus Releases DILIsym® X
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus released DILIsym X, its flagship QST platform, with important enhancements to expedite and improve predictions regarding drug safety.
Simulations Plus Releases ADMET Predictor® Version 12
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus releases ADMET Predictor 12, a major upgrade to its machine-learning modeling platform for drug discovery, design, & optimization.
Simulations Plus to Participate in KeyBanc's 25th Annual Technology Leadership Forum
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be presenting at KeyBanc's 25th Annual Technology Leadership Forum in Vail, CO, on Monday, August 5, 2024.
Simulations Plus Announces New Research Project with the International Collaboration on Cosmetics Safety
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus was selected for a new project with the International Collaboration on Cosmetics Safety to advance animal-free safety assessments.
Simulations Plus Posts Q3 Results, Joins First Foundation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq futures falling around 0.2% on Wednesday.
Simulations Plus, Inc. (SLP) Q3 2024 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP) Q3 2024 Earnings Conference Call July 2, 2024 5:00 PM ET Company Participants Lisa Fortuna - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executiv...
Simulations Plus Reports Third Quarter Fiscal 2024 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported 3QFY24 total revenue of $18.5 million, up 14% over 3QFY23, and 9 months FY24 total revenue of $51.3 million, up 17%.
Simulations Plus to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be participating in Morgan Stanley's 3rd Annual Life Sciences AI Summit on June 26, 2024, in New York City.
Simulations Plus Announces Third Quarter Fiscal Year 2024 Earnings and Conference Call Date
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will report 3rd quarter FY24 earnings and host a conference call to discuss the financial results on July 2, 2024, at 5pm EDT.
QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus
RALEIGH, N.C.--(BUSINESS WIRE)--QHP Capital-Backed Pro-ficiency Acquired by Simulations Plus.
Simulations Plus Acquires Pro-ficiency, Creating One-of-a-Kind Platform Spanning the Drug Development Continuum
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the acquisition of Pro-ficiency with simulation-enabled solutions to expand and enhance the Company's offerings.
Simulations Plus to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus CEO, Shawn O'Connor, will be participating in Craig-Hallum's 21st Annual Institutional Investor Conference on May 29, in Minneapolis.
Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the release of the completely redesigned GastroPlusX (GPX), the next generation PBPK/PBBM modeling & simulation software.
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the US FDA has again renewed licenses to its DILIsym QST software to support informed decision-making in drug approvals.